Vemurafenib for treating locally advanced or metastatic BRAF V600 mutation-positive malignant melanoma

View the summary and implementation tools

This is an extract from the guidance. The complete guidance is available at guidance.nice.org.uk/ta269

1 Guidance

1.1 Vemurafenib is recommended as an option for treating BRAF V600 mutation-positive unresectable or metastatic melanoma only if the manufacturer provides vemurafenib with the discount agreed in the patient access scheme.